Bristol-Myers Squibb said that it has been granted the exclusive right to buy privately held Promedior and its experimental fibrosis treatment for up to $1.25 billion.
WSJ.com: Health, Wall Street Journal: Business: Health
Mon, 08/31/2015 - 2:29pm
Bristol-Myers Squibb said that it has been granted the exclusive right to buy privately held Promedior and its experimental fibrosis treatment for up to $1.25 billion.